Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP26A1 | O43174 | 2/20 | 0.45 |
| ▸ | CYP26B1 | Q9NR63 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8729047 | 0.80 | CYP26A1 (0.35) | CYP26A1CYP26B1 | |
| SCHEMBL7190672 | 0.76 | CYP26A1 (0.33) | CYP26A1CYP26B1 | |
| SCHEMBL8733963 | 0.74 | TDP1 (0.41) | CYP26A1CYP26B1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL7740691 | 0.72 | MEN1 (0.47) | LMNASMN1; SMN2 | |
| SCHEMBL7156039 | 0.71 | CYP26A1 (0.49) | CYP26A1CYP26B1 | |
| SCHEMBL8561686 | 0.71 | AKR1B1 (0.35) | CYP26A1CYP26B1ALDH1A1 | |
| SCHEMBL13805575 | 0.71 | HPGD (0.35) | ALDH1A1HTR2CKDM4EHPGDLMNA | |
| SCHEMBL15397113 | 0.70 | HNF4A (0.35) | ALDH1A1HTR2CKDM4EHPGDBRD4 | |
| SCHEMBL435089 | 0.69 | LMNA (0.49) | ALDH1A1KDM4ELMNASMN1; SMN2 | |
| SCHEMBL23449322 | 0.68 | CD44 (0.33) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10874634-B2 | Compounds and methods for inhibiting CYP26 enzymes | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2020-12-29 | — | — | US | disclosed |
| US-6610744-B2 | Administering to a mammal a retinoid campound which binds specifically or selectively to a RAR alpha retinoid receptors in preference over RAR beta and RAR Gamma retinoid receptors, for therapy and prophylaxisof disease or condition | ALLERGAN, INC. | 2003-08-26 | — | — | US | disclosed |
| US-6534544-B1 | Administering retinoid compound as anticarcinogenic and antitumor agents; side effect reduction | ALLERGAN SALES, INC. | 2003-03-18 | — | — | US | disclosed |
| US-20020077360-A1 | Methods of treatment with compounds having RAR alpha receptor specific or selective activity | ALLERGAN SALES, INC. | 2002-06-20 | — | — | US | disclosed |
| US-6342602-B1 | BIND SPECIFICALLY OR SELECTIVELY TO RAR-ALPHA RECEPTORS | ALLERGAN SALES, INC. | 2002-01-29 | — | — | US | disclosed |
| EP-0876330-B1 | ARYL OR HETEROARYL AMIDES OF TETRAHYDRONAPHTHALENE, CHROMAN, THIOCHROMAN AND 1,2,3,4-TETRAHYDROQUINOLINE CARBOXYLIC ACIDS HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY | ALLERGAN SALES INC (US) | 2001-03-28 | — | — | EP | disclosed |
| US-6124455-A | Aryl or heteroaryl amides of tetrahydronaphthalene, chroman, thiochroman and 1,2,3,4-tetrahydroquinoline carboxylic acids, having an electron withdrawing substituent in the aromatic or heteroaromatic moiety, having retinoid-like biological activity | ALLERGAN SALES, INC. (US) | 2000-09-26 | — | — | US | disclosed |
| US-6034244-A | ANTIINFLAMMATORY AGENTS; SKIN DISORDERS; ANTICANCER AGENT | ALLERGAN SALES, INC. (US) | 2000-03-07 | — | — | US | disclosed |
| US-5965606-A | RETINOID RECEPTORS, 2-FLUORO-4-(2',2',4',4'-TETRAMETHYL-8'-TRIFLUOROMETHYLCHROMAN-6' -YL)CARBAMOYL BENZOIC ACID FOR TREATING MONOCYTIC LEUKEMIA | ALLERGAN SALES, INC. (US) | 1999-10-12 | — | — | US | disclosed |
| US-5856490-A | Aryl or heteroaryl amides of tetrahydronaphthalene, chroman, thiochroman and 1,2,3,4-tetrahydroquinoline carboxylic acids, having an electron withdrawing substituent in the aromatic or heteroaromatic moiety, having retinoid-like biological activity | ALLERGAN (US) | 1999-01-05 | — | — | US | disclosed |
| EP-0876330-A1 | ARYL OR HETEROARYL AMIDES OF TETRAHYDRONAPHTHALENE, CHROMAN, THIOCHROMAN AND 1,2,3,4-TETRAHYDROQUINOLINE CARBOXYLIC ACIDS HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY | Allergan (US) | 1998-11-11 | — | — | EP | disclosed |
| EP-0869782-A2 | METHODS OF TREATMENT WITH COMPOUNDS HAVING RAR $g(a)? RECEPTOR SPECIFIC OR SELECTIVE ACTIVITY | Vision Pharmaceuticals L.P. (US) | 1998-10-14 | — | — | EP | disclosed |
| US-5675024-A | RETINOID RECEPTOR AGONISTS | ALLERGAN (US) | 1997-10-07 | — | — | US | disclosed |
| WO-1997024116-A2 | METHODS OF TREATMENT WITH COMPOUNDS HAVING RARα RECEPTOR SPECIFIC OR SELECTIVE ACTIVITY | VISION PHARMACEUTICALS L.P. (US) | 1997-07-10 | — | — | WO | disclosed |
| WO-1997019052-A1 | ARYL OR HETEROARYL AMIDES OF TETRAHYDRONAPHTHALENE, CHROMAN, THIOCHROMAN AND 1,2,3,4-TETRAHYDROQUINOLINE CARBOXYLIC ACIDS HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY | ALLERGAN (US) | 1997-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020077360-A1 | Methods of treatment with compounds having RAR alpha receptor specific or selective activity | RARG, RARA, RARB | CYP26A1 269/4885CYP26B1 305/4885ALDH1A1 391/4885 |
| US-10874634-B2 | Compounds and methods for inhibiting CYP26 enzymes | CYP26B1, CYP2A6, CYP26A1 | CYP26A1 3/4885CYP26B1 1/4885ALDH1A1 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.